Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Hasbro, Inc. (HAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Hasbro, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Hasbro, Inc. trades at $79.12 (market cap $11.17B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.6× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 3.55% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | HAS | |
|---|---|---|
Market Cap | $39.89B | $11.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $105.88 |
52-Week Low | $278.09 | $70.95 |
Enterprise Value | $38.15B | $13.44B |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Hasbro (HAS) trades at $78.96, up 2.03% today, with a bearish technical signal but bullish oscillators suggesting potential reversal. The company reported negative net income of -$322.4M in 2025 despite revenue growth to $4.7B. Recent earnings beats and a $0.70 dividend highlight operational resilience, while analyst consensus targets $104.80. News highlights include new product launches like Blooms by Play-Doh and strong performance in the Wizards segment.
Outlook: Upside exists from analyst targets and earnings momentum, but risks include high debt, margin pressure, and competitive threats. The stock presents a contrarian opportunity if operational improvements continue, though volatility near key support at $76 warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
